■为了评估法利单抗注射治疗初治新生血管性年龄相关性黄斑变性(nvAMD)患者的疗效和安全性,包括亚型和螺旋状脉络膜表型,并确定视觉结果的预测因素。
■nvAMD患者被前瞻性招募,接受三个月的法利单抗(6毫克)注射。在末次注射后两个月(第4个月)的最佳矫正视力(BCVA)在亚型之间进行比较,在硬脉络膜新生血管病变(PNV)和非PNV眼之间。回归分析确定影响第4个月BCVA的因素。
■该研究涉及23名患者(12名典型的AMD[tAMD],10息肉状脉络膜血管病变[PCV],1视网膜血管瘤增生[RAP])。11例表现为PNV表型。法利单抗治疗后观察到BCVA(P=4.9×10-4)和中央视网膜厚度(CRT)(P=1.3×10-5)的显着改善。该疗法对tAMD和PCV眼都显示出良好的结果,以及非PNV和PNV眼睛。Faricimab在77.3%的眼睛中实现了黄斑干燥,在大多数情况下,视网膜下液的分辨率,尽管视网膜内液体(IRF)经常持续存在。多变量分析在第4个月确定了外部限制膜(ELM)的存在和IRF为BCVA贡献者。
■Faricimab在初治nvAMD患者中表现出显著的有效性和安全性,特别是PCV和PNV眼睛。ELM的存在和IRF是视觉结果的预测。
UNASSIGNED: To evaluate the efficacy and safety of faricimab injections for treatment-naïve neovascular age-related macular degeneration (nvAMD) patients, including subtypes and pachychoroid phenotypes, and identify predictive factors for visual outcomes.
UNASSIGNED: nvAMD patients were prospectively recruited, receiving three monthly faricimab (6 mg) injections. Best-corrected visual acuity (BCVA) two months after the last injection (month 4) was compared between subtypes, and between pachychoroid neovasculopathy (PNV) and non-PNV eyes. Regression analysis determined factors influencing month 4 BCVA.
UNASSIGNED: The study involved 23 patients (12 typical AMD [tAMD], 10 polypoidal choroidal vasculopathy [PCV], 1 retinal angiomatous proliferation [RAP]). Eleven exhibited PNV phenotype. Significant BCVA (P = 4.9 × 10-4) and central retinal thickness (CRT) (P = 1.3 × 10-5) improvements were observed post-faricimab treatment. The therapy demonstrated favourable results for both tAMD and PCV eyes, and non-PNV and PNV eyes. Faricimab achieved dry macula in 77.3% of eyes, with subretinal fluid resolution in most cases, although intraretinal fluid (
IRF) often persisted. Multivariable analysis identified external limiting membrane (ELM) presence and
IRF as BCVA contributors at month 4.
UNASSIGNED: Faricimab demonstrated significant effectiveness and safety in treatment-naïve nvAMD patients, particularly for PCV and PNV eyes. ELM presence and
IRF is predictive of visual outcomes.